The Celiac Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Celiac Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Celiac Disease and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Celiac Disease by 31 companies/universities/institutes. The top development phase for Celiac Disease is phase i with ten drugs in that stage. The Celiac Disease pipeline has 34 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Celiac Disease pipeline products market are: Takeda Pharmaceutical, Pfizer and Zedira.
The key targets in the Celiac Disease pipeline products market include Interleukin 15, Interleukin 2 Receptor Subunit Beta, and Tyrosine Protein Kinase JAK3.
The key mechanisms of action in the Celiac Disease pipeline product include Interleukin 15 Inhibitor with four drugs in Phase II. The Celiac Disease pipeline products include five routes of administration with the top ROA being Oral and 14 key molecule types in the Celiac Disease pipeline products market including Monoclonal Antibody, and Small Molecule.
Celiac Disease overview
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain, and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome, and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Treatment also involves adhering to strict gluten-free diet.
For a complete picture of Celiac Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
